Cargando…

BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer

SIMPLE SUMMARY: Thyroid cancer is the most common endocrine malignancy. Patients with advanced thyroid cancers have poor survival rates, largely because of limited therapeutic options to combat their aggressive nature, creating a compelling need to identify novel therapeutic targets. We and others h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rose, Madison M., Espinoza, Veronica L., Hoff, Katelyn J., Pike, Laura A., Sharma, Vibha, Hofmann, Marie-Claude, Tan, Aik Choon, Pozdeyev, Nikita, Schweppe, Rebecca E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856535/ https://www.ncbi.nlm.nih.gov/pubmed/36672327 http://dx.doi.org/10.3390/cancers15020378

Ejemplares similares

Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
por: Beadnell, Thomas C., et al.
Publicado: (2018)

Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis
por: Kessler, Brittelle E., et al.
Publicado: (2018)

Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies
por: Pozdeyev, Nikita, et al.
Publicado: (2016)

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019)

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
por: Ferguson, Jennifer, et al.
Publicado: (2012)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
por: Boudny, V, et al.
Publicado: (2002)

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
por: Lui, Goldie Y.L., et al.
Publicado: (2020)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
por: Hur, Eun-Hye, et al.
Publicado: (2017)

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo
por: Fan, Fan, et al.
Publicado: (2023)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
por: Korfi, K, et al.
Publicado: (2016)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
por: Beuret, Laurent, et al.
Publicado: (2021)

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report
por: Schreiber, Anna R, et al.
Publicado: (2020)

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment
por: Dawson, John C., et al.
Publicado: (2021)

Status of PIP2 at FNAL
por: Pozdeyev, Eduard
Publicado: (2019)

P998: REGULATION OF BCL-X SPLICING BY SRC KINASES INHIBITORS IN MYELOPROLIFERATIVE NEOPLASMS
por: Petiti, J., et al.
Publicado: (2022)

Epithelial-Mesenchymal Transition of Ovarian Cancer Cells Is Sustained by Rac1 through Simultaneous Activation of MEK1/2 and Src Signaling Pathways
por: Fang, Dongdong, et al.
Publicado: (2016)

Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation
por: Roy, H K, et al.
Publicado: (2001)

Neuroprotective Action of Cycloheximide Involves Induction of Bcl-2 and Antioxidant Pathways
por: Furukawa, Katsutoshi, et al.
Publicado: (1997)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation
por: Lin, Tsung-Yao, et al.
Publicado: (2015)

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
por: Kupryjańczyk, J, et al.
Publicado: (2003)

Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis
por: Hartig, Sean M., et al.
Publicado: (2011)

PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells
por: Wood, William M., et al.
Publicado: (2011)

Integrin β5 contributes to the tumorigenic potential of breast cancer cells through Src-FAK and MEK-ERK signaling pathways
por: Bianchi-Smiraglia, Anna, et al.
Publicado: (2012)

Effect of carboplatin injection on Bcl-2 protein expression and apoptosis induction in Raji cells
por: Lin, Peng, et al.
Publicado: (2020)

Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer
por: Morrison, Jennifer A, et al.
Publicado: (2014)

NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression
por: Chen, Junying, et al.
Publicado: (2015)

Cisplatin inhibits MEK1/2
por: Yamamoto, Tetsu, et al.
Publicado: (2015)

SAT-574 Elucidating the Role of Nuclear Focal Adhesion Kinase (FAK) in Thyroid Cancer
por: Kellett, Meghan, et al.
Publicado: (2019)

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
por: Booth, Laurence, et al.
Publicado: (2021)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Blockade of the SRC/STAT3/BCL-2 Signaling Axis Sustains the Cytotoxicity in Human Colorectal Cancer Cell Lines Induced by Dehydroxyhispolon Methyl Ether
por: Hsieh, Ya-Chu, et al.
Publicado: (2023)

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
por: Meng, Jieru, et al.
Publicado: (2010)

The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?
por: Luo, Xu, et al.
Publicado: (2020)

Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity
por: Liu, Wei, et al.
Publicado: (2020)

BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_llla0tikn60at2umbfkqrd4cr6